Patrick Rossignol News Today

Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.

Plus: bardoxolone methyl for diabetic kidney disease and spironolactone in hemodialysis patients

At ASN Kidney Week 2023, we collected perspectives from 10 key opinion leaders in nephrology on what they see as the most significant news in their specialty from the past year.

Patrick Rossignol, MD, PhD, provides additional perspective on the results of the ALCHEMIST trial from Kidney Week 2023.

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.

Primary results presented at ASN Kidney Week 2023 showed spironolactone missed the trial's primary endpoint.

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.

The first Heart Day in Monaco has brought together specialists to raise awareness discuss the latest innovative solutions to treating heart disease, something that kills one in two women globally.

Porto, Portugal: Recent data from the ACCORD Lipid trial showed that fenofibrate reduces the composite of HF hospitalizations or cardiovascular mortality in type 2 diabetes (T2D) patients treated with...

France: A new study by Patrick Rossignol and the team revealed that recurrent hyperkalemia (HK) is associated with RAASi discontinuation and dose lowering. Among those with recurrent HK, HK is the...